Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase 3 multicenter, open-label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setting.
Deeb LC, Dulude H, Guzman CB, Zhang S, Reiner BJ, Piché CA, Pradhan S, Zhang XM. Deeb LC, et al. Among authors: piche ca. Pediatr Diabetes. 2018 Aug;19(5):1007-1013. doi: 10.1111/pedi.12668. Epub 2018 Mar 22. Pediatr Diabetes. 2018. PMID: 29512902 Clinical Trial.
Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real-world setting.
Seaquist ER, Dulude H, Zhang XM, Rabasa-Lhoret R, Tsoukas GM, Conway JR, Weisnagel SJ, Gerety G, Woo VC, Zhang S, Carballo D, Pradhan S, Piché CA, Guzman CB. Seaquist ER, et al. Among authors: piche ca. Diabetes Obes Metab. 2018 May;20(5):1316-1320. doi: 10.1111/dom.13278. Epub 2018 Mar 22. Diabetes Obes Metab. 2018. PMID: 29504662 Free PMC article. Clinical Trial.
Effects of common cold and concomitant administration of nasal decongestant on the pharmacokinetics and pharmacodynamics of nasal glucagon in otherwise healthy participants: A randomized clinical trial.
Guzman CB, Dulude H, Piché C, Rufiange M, Sadoune AA, Rampakakis E, Carballo D, Triest M, Zhang MX, Zhang S, Tafreshi M, Sicard E. Guzman CB, et al. Among authors: piche c. Diabetes Obes Metab. 2018 Mar;20(3):646-653. doi: 10.1111/dom.13134. Epub 2017 Nov 19. Diabetes Obes Metab. 2018. PMID: 29053231 Free PMC article. Clinical Trial.
Faster Use and Fewer Failures with Needle-Free Nasal Glucagon Versus Injectable Glucagon in Severe Hypoglycemia Rescue: A Simulation Study.
Yale JF, Dulude H, Egeth M, Piché CA, Lafontaine M, Carballo D, Margolies R, Dissinger E, Shames AR, Kaplowitz N, Zhang MX, Zhang S, Guzman CB. Yale JF, et al. Among authors: piche ca. Diabetes Technol Ther. 2017 Jul;19(7):423-432. doi: 10.1089/dia.2016.0460. Epub 2017 May 30. Diabetes Technol Ther. 2017. PMID: 28556672 Free PMC article.
Response to Comment on Rickels et al. Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. Diabetes Care 2016;39:264-270.
Rickels MR, Ruedy KJ, Foster NC, Piché CA, Dulude H, Sherr JL, Tamborlane WV, Bethin KE, DiMeglio LA, Wadwa RP, Ahmann AJ, Haller MJ, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW; T1D Exchange Intranasal Glucagon Investigators. Rickels MR, et al. Among authors: piche ca. Diabetes Care. 2016 Oct;39(10):e193-4. doi: 10.2337/dci16-0025. Diabetes Care. 2016. PMID: 27660135 Free PMC article. No abstract available.
Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes.
Sherr JL, Ruedy KJ, Foster NC, Piché CA, Dulude H, Rickels MR, Tamborlane WV, Bethin KE, DiMeglio LA, Fox LA, Wadwa RP, Schatz DA, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW; T1D Exchange Intranasal Glucagon Investigators. Sherr JL, et al. Among authors: piche ca. Diabetes Care. 2016 Apr;39(4):555-62. doi: 10.2337/dc15-1606. Epub 2016 Feb 16. Diabetes Care. 2016. PMID: 26884472 Free PMC article. Clinical Trial.
46 results